Ascendia Pharmaceuticals Named to Inc. 5000 List for Third Consecutive Year

Sep 8, 2022 12:00:00 AM

Steps to Overcome Challenges Associated with Biologic Formulation Development

Aug 22, 2022 12:00:00 AM

Ascendia Pharmaceuticals Included in 2022 United States Life Sciences Report

Jul 7, 2022 12:00:00 AM

Ascendia Pharmaceuticals Provides Perspective on Life Science Market During CPHI North America

Jun 27, 2022 12:00:00 AM

Ascendia CEO Presents on Gene Therapy Drug Delivery Technologies at SAPA Event

Jun 20, 2022 12:00:00 AM

How Various Clinical Study Stages Influences Oral Formulation Approach

Apr 4, 2022 12:00:00 AM

Ascendia to Attend DCAT Week

Mar 11, 2022 12:00:00 AM

Developing an Effective Lipid Nanoparticle Formulation Process for Small Molecule and Biologicals Delivery

Feb 21, 2022 12:00:00 AM

Amorphous Nanoparticles for Drug Delivery of Poorly Water-Soluble Compounds

Jan 18, 2022 12:00:00 AM

Ascendia Pharmaceuticals Participates in Virtual Nasdaq Opening Bell Ceremony Celebrating J.P. Morgan Healthcare Conference

Jan 14, 2022 12:00:00 AM

Ascendia Solidifies Leading CDMO Position By Ranking on Inc. 5000 List Again

Oct 12, 2021 12:00:00 AM

Ascendia to Highlight CDMO Services at AAPS PharmSci360

Oct 7, 2021 12:00:00 AM